How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,946 results for

Hormonally Active Chemotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO

Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES August, 01 2017 December, 20 2017 ARTICLE CITATION DOI: 10.1200/JCO.2017.72.8030 Journal (...) of Clinical Oncology - published online before print April 25, 2017 PMID: Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion x Katherine S. Virgo , x Ethan Basch , x D. Andrew Loblaw , x Thomas K. Oliver , x R. Bryan Rumble , x Michael A. Carducci , x Luke Nordquist , x Mary-Ellen Taplin , x Eric Winquist , and x Eric A. Singer Katherine S. Virgo, Emory University, Atlanta, GA; Ethan Basch

2017 American Society of Clinical Oncology Guidelines

2. Hormonally Active Chemotherapy

Hormonally Active Chemotherapy Hormonally Active Chemotherapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hormonally Active (...) Chemotherapy Hormonally Active Chemotherapy Aka: Hormonally Active Chemotherapy From Related Chapters II. Agents Antiestrogen Antiandrogen Flutamide (Eulexin) s Leuprolide acetate (Lupron) Aromatase Inhibitors Aminoglutethimide (Cytadren) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Hormonally Active Chemotherapy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip

2018 FP Notebook

3. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

not include a survival adjustment for cabazitaxel (see section 3.20).The company did not adjust for other active treatments that were Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 48used by some patients in COU-AA-302 but are not used in the NHS after abiraterone, including sipuleucel-T (the marketing (...) Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Abir Abiraterone for treating metastatic aterone for treating metastatic hormone-relapsed prostate cancer hormone-relapsed prostate cancer before chemother before chemotherap apy is indicated y is indicated T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta387 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Enzalutamide for treating metastatic Enzalutamide for treating metastatic hormone-relapsed prostate cancer hormone-relapsed prostate cancer before chemother before chemotherap apy is indicated y is indicated T echnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta377 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377) © NICE 2019. All rights reserved

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

5. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment (PubMed)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC.CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein (...) kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids.Binimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring KRAS mutations.

Full Text available with Trip Pro

2018 Gynecologic Oncology Reports

6. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

in the treatment of prostate cancer. Therefore, using enzalutamide at this earlier position in the treatment pathway would mean that neither it nor abiraterone would be an option later (either before or after chemotherapy) once the cancer has metastasised. Experience of people with prostate cancer Prostate cancer causes few symptoms until metastases occur Prostate cancer causes few symptoms until metastases occur 3.2 Patient experts commented that most people with hormone-relapsed non- metastatic prostate (...) The committee discussed whether the relative effectiveness of enzalutamide at later points in the treatment pathway could provide insight into its survival benefit in the hormone-relapsed non-metastatic setting. In this setting (see section 3.8), the hazard ratio for overall survival was 0.83 (95% CI 0.65 to 1.06). This compared with hazard ratios later in the treatment pathway (that is, for hormone-relapsed metastatic disease) of 0.76 (95% CI 0.66 to 0.88) in the pre- chemotherapy setting and 0.62 (95% CI

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

7. Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers (...) : refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy The safety and scientific validity

2017 Clinical Trials

8. A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (...) Purpose: Treatment Official Title: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). Actual Study Start Date : March 1, 2018 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 31, 2021 Resource links provided by the National Library

2017 Clinical Trials

9. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. (PubMed)

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. We examined whether genetic polymorphisms (SNPs) in the capecitabine activation pathway and CDA enzymatic activity were associated with prognosis, benefit from capecitabine-containing treatment or capecitabine-related toxicities. The study population comprised 188 metastatic breast cancer (...) variable. CDA c.-33delC was prognostic for overall survival (OS) independent of hormone receptor status. For the predictive analysis, progression-free survival benefit from ATX over AT was observed in patients with a CDA c.-33del/del or del/insC genotype, a CDA c.-451CC or CT genotype, and a CES2 c.-806CC genotype compared with their counterparts. There was a higher response rate for ATX over AT in patients with a CDA c.-451CT or TT genotype. Patients with high CDA enzymatic activity had more benefit

2018 Pharmacological Research

10. Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study. (PubMed)

of angiotensin II (AngII) when compared to healthy individuals, although specific enzyme activities were different between pre- and post- menopausal women. In addition, neoadjuvant chemotherapy in breast cancer patients caused changes in aminopeptidase activities leading to increased AngII catabolism independently of hormonal status. Here we extend the aminopeptidase analysis to three time points of the patient follow-up (6, 12, and 24 months). No changes occur in enzyme activities during this time period (...) Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study. We have previously described changes in several circulating renin-angiotensin system (RAS)-regulating aminopeptidase activities in pre- and postmenopausal women with breast cancer treated or not with neoadjuvant chemotherapy. Women with breast cancer presented a reduced catabolism

2018 Breast

11. Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety (PubMed)

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which (...) . The disease control rate (DCR) was 73.1%, with no statistically significant difference among the different settings. At a median follow-up of 42 months, the median progression free survival (PFS) was 11.6, 9.7 and 7.5 months for patients treated with Exe-Eve as first, second or third line therapy, respectively. There was a statistically significant correlation with younger age, no previous adjuvant chemotherapy (CT), no previous adjuvant endocrine therapy (ET), HT duration ≥36 months, involvement of liver

Full Text available with Trip Pro

2018 Molecular and clinical oncology

12. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway (PubMed)

Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, and systemic chemotherapy is the major treatment strategy for late-stage HCC patients. Poor prognosis following chemotherapy is the general outcome owing to recurrent resistance. Recent studies have suggested that in addition to cytotoxic effects (...) on tumor cells, chemotherapy can induce an alternative cascade that supports tumor growth and metastasis. In the present investigation, we showed that thyroid hormone (TH), a potent hormone-mediating cellular differentiation and metabolism, acts as an antiapoptosis factor upon challenge of thyroid hormone receptor (TR)-expressing HCC cells with cancer therapy drugs, including cisplatin, doxorubicin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TH/TR signaling promoted

Full Text available with Trip Pro

2016 Cell death & disease

13. Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2016 Clinical Trials

14. A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy

A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider

2016 Clinical Trials

15. Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02728622 Recruitment Status : Completed First

2016 Clinical Trials

16. Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary (...) Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

2016 Clinical Trials

17. Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles. (PubMed)

Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles. To evaluate reproductive hormone patterns in women exposed to alkylating-agent chemotherapy.Prospective cohort.University hospital.Normally menstruating mid-reproductive-age women (20-35 years old) who had previously been exposed to alkylating-agent chemotherapy for cancer treatment were compared with two healthy control populations: similarly-aged women and late-reproductive-age women (...) (43-50 years old).Subjects collected daily urine samples for one cycle.Integrated urinary pregnanediol glucuronide (PDG) and estrone conjugate (E1c) and urinary excretion of gonadotropins (FSH and LH).Thirty-eight women (13 survivors, 11 same-age control subjects, 14 late-reproductive-age control subjects) provided 1,082 urine samples. Cycle length, luteal phase length, and evidence of luteal activity were similar among the groups. As expected, ovarian reserve was impaired in cancer survivors

Full Text available with Trip Pro

2016 Fertility and Sterility

18. Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap

Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap 1 1 SMC2179 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy

2019 Scottish Medicines Consortium

19. Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t

with an aromatase inhibitor to control their disease. This combination can extend the time that patients’ are able to live without their condition progressing. Progression free survival is important to patients as it enables them to continue with their normal activities for as long as possible and spend quality time with their family and friends. It may also delay the time to chemotherapy which is an important outcome for patients because of the gruelling side effects associated with chemotherapy. ? Abemaciclib (...) Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t 1 Published 13 May 2019 1 SMC2135 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

2019 Scottish Medicines Consortium

20. The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care

pregnancy assessed the predictability of a single serum antimüllerian hormone level for pregnancy during the next six menstrual cycles. The monthly probability of pregnancy in women with low serum antimüllerian hormone levels (defined as less than or equal to 10 pm ol/L or approximately 1.4 ng/mL) did not differ from that of women with normal serum antimüllerian hormone levels ( ). More recently, a study of 750 women who were not infertile and were actively trying to become pregnant found no association (...) are not part of the accepted diagnostic criteria for PCOS. Antimüllerian Hormone as an Assessment of Ovarian Reserve After Gonadotoxic Therapy Survival rates for reproductive-aged women with cancer have continued to improve over the years. Appropriately, this has resulted in increased attention to the effects of gonadotoxic chemotherapy on long-term ovarian function and fertility potential ( ). Although pretreatment antimüllerian hormone levels may help predict menses and the potential for extended

2019 American College of Obstetricians and Gynecologists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>